Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from ABPI

Dozens of MPs oppose Streeting’s new power to say what NHS pays for drugs

Health secretary’s ‘power grab’ to override Nice comes amid growing concern move may be illegal and benefit big pharma

The Guardian - UK

HRT maker censured by UK regulator for ‘systemic failures’ that put patients at risk

Drug industry’s self-regulatory body criticises Theramex, producer of Evorel and Intrarosa, for ‘alarming’ breaches

The Guardian - UK

Pharma giant ditches £1bn London research hub and says UK ‘is not internationally competitive’

Merck, known as MSD in Europe, criticised the UK’s business environment despite the government saying it has become ‘the most attractive place to invest in the world’

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Streeting vows not to let drug firms ‘rip off’ taxpayers after pricing row

The Health Secretary on Friday left talks with the pharmaceuticals sector after both sides failed to agree changes to a drug pricing deal.

Evening Standard

What is the row between Wes Streeting and pharmaceutical companies about?

Health secretary has accused firms of being ‘shortsighted’ during dispute over terms for provision of drugs to the NHS

The Guardian - UK

Wes Streeting criticises ‘shortsighted’ drug firms for rejecting pricing offer

Exclusive: Health secretary says he will not let patients be ‘ripped off’ by pharmaceutical companies amid standoff

The Guardian - UK

Wes Streeting’s row with pharma firms grows as they reject NHS drug pricing offer

Drugmakers reject health secretary’s latest offer, meaning ‘unsustainable’ rebate scheme will stay in place

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Offer to increase UK spending on medicines shelved, Government says

Officials launched a review of the voluntary scheme for branded medicines pricing, access and growth earlier this year.

Evening Standard

Clinical trial hubs to open as part of £400m public-private investment

The 18 new Commercial Research Delivery Centres are intended to bolster the UK’s trials infrastructure and support the recruitment of patients.

The Independent UK

‘It’s naive to think this is in the best interests of the NHS.’ How Big Pharma’s millions are influencing healthcare

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

The Guardian - UK

Plunge in clinical drug trials makes Britain an urgent case for treatment

With visions of the UK as a ‘life sciences superpower’ at risk, we report from Great Ormond Street hospital on what’s being done to give children access to new drugs

The Guardian - UK

Revealed: maker of Wegovy ‘skinny jab’ is funding NHS weight-loss services

Critics fear conflict of interest as Novo Nordisk helps medics ‘reduce unnecessary barriers’ to treatment for obesity

The Guardian - UK

‘Skinny jab’ drug firm facing fresh inquiries after ‘serious breaches’ of industry code

Pharmaceutical company behind blockbuster diet jab Wegovy confronts crises on multiple fronts, amid scrutiny of UK activities

The Guardian - UK

Firm behind Wegovy slimming jab suspended from UK trade association

Novo Nordisk found to be in breach of ABPI code of practice over sponsored weight-loss courses that promoted its medicines

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Ignore the ‘superpower’ boasts – UK pharma looks superchallenged

NHS crisis, withdrawal of tax credits and exit from EU blamed for fall in UK share of R&D market

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Great Ormond Street Hospital

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.